Breakthrough pre-clinical,
research findings to be released show therapeutic advancements on
the data-driven evolution of psychedelic psilocybin
molecule
TORONTO, Canada -- November 2, 2021 -- InvestorsHub NewsWire
-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin"
or the "Company"), a biopharmaceutical company
focused on progressing "Psychedelics to Therapeutics™", will host
an in-person and virtual research and development ("R&D")
briefing releasing positive research findings and data on Monday,
November 8, 2021 from 8:30 am to 9:30 am (EST) on the advancements
to create a promising approach for patients in need of effective
and safe prescription therapies in the mental health space. Founded
in October 2019, Cybin is a company that has evolved in many ways
on its journey to create ethical and equitable scientific
platforms.
Cybin's leadership, including CEO Doug Drysdale and the
Company's senior scientific research team, are hosting the R&D
briefing. The in-person session will take place at
the Adrienne Arsht Center for the Performing Arts,
within the Green Room, at the Wonderland Conference in Miami.
Log-in details for the webcast for virtual attendees can be found
below. The event will be followed by a Q&A session.
The evolution within the Company continues to align with its
"Psychedelics to Therapeutics" approach by harnessing already known
attributes of classical psychedelics and engineering them into
commercially viable therapeutics. The Company's comparative
pre-clinical data clearly shows multiple potential advantages over
classical psychedelic molecules. This data and the molecular
possibilities may have wide-reaching implications for the treatment
of mental health.
"We are on a mission to create safe and effective therapeutics
for patients to address a multitude of mental health issues. At a
time when COVID has exacerbated the mental health crisis to
epidemic proportions, the Cybin team has been exceptionally
productive. We are excited to share the deeply meaningful
scientific progress that we have made. You will not want to miss
this," said Drysdale.
Speakers at the R&D event include:
Doug Drysdale – Chief Executive Officer
Michael Palfreyman, Ph.D. – Chief R&D Officer
Geoff Varty, Ph.D. – Head of R&D
Aaron Bartlone – Chief Operating Officer
Physical address for attendees:
Physical event is for media attendees and analysts only. To
RSVP, please email info@cybin.com.
The Adrienne Arsht Center for the Performing
Arts
Next Generation Green Room
Arts of Miami-Dade County, Inc.
1300 Biscayne Blvd. Miami, FL 33132
Virtual Webcast:
Virtual event is open to shareholders and the general
public.
Topic: Cybin Research & Development Press Conference
Location: Wonderland Conference, Miami, FL
Time: Nov 8, 2021 08:30 AM Eastern Time (US and Canada)
Join Zoom Meeting
https://imageav.zoom.us/j/82993672583?pwd=cW9zQi9Xc1BCbExpTGh5T09aS1hGUT09
One tap mobile
+13462487799,,82993672583#,,,,*730988# US
Dial by your location
Meeting ID: 829 9367 2583
Passcode: 730988
Find your local number: https://imageav.zoom.us/u/kWOoByjaK
About Cybin
Cybin is a leading ethical biopharmaceutical company, working
with a network of world-class partners and
internationally-recognized scientists, on a mission to create safe
and effective therapeutics for patients to address a multitude of
mental health issues. Headquartered in Canada and founded in 2019,
Cybin is operational in the USA, UK and Ireland. The Company is
focused on progressing Psychedelics to Therapeutics by engineering
proprietary drug discovery platforms, innovative drug delivery
systems, novel formulation approaches and treatment regimens for
mental health disorders.
Cautionary Notes and Forward-Looking
Statements
Certain statements in this press release constitute
forward-looking information. All statements other than statements
of historical fact contained in this press release, including,
without limitation, statements regarding Cybin's future, strategy,
plans, objectives, goals and targets, and any statements preceded
by, followed by or that include the words "believe", "expect",
"aim", "intend", "plan", "continue", "will", "may", "would",
"anticipate", "estimate", "forecast", "predict", "project", "seek",
"should" or similar expressions or the negative thereof, are
forward-looking statements. Forward-looking statements in this news
release include statements regarding the Company's proprietary drug
discovery platforms, innovative drug delivery systems, novel
formulation approaches and treatment regimens to potentially treat
psychiatric disorders.
These forward-looking statements are based on reasonable
assumptions and estimates of management of the Company at the time
such statements were made. Actual future results may differ
materially as forward-looking statements involve known and unknown
risks, uncertainties, and other factors which may cause the actual
results, performance, or achievements of the Company to materially
differ from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Such
factors, among other things, include: implications of the COVID-19
pandemic on the Company's operations; fluctuations in general
macroeconomic conditions; fluctuations in securities markets;
expectations regarding the size of the psychedelics market; the
ability of the Company to successfully achieve its business
objectives; plans for growth; political, social and environmental
uncertainties; employee relations; the presence of laws and
regulations that may impose restrictions in the markets where the
Company operates; and the risk factors set out in the Company's
management's discussion and analysis for the period ended June 30,
2021 and the Company's listing statement dated November 9, 2020,
which are available under the Company's profile on www.sedar.com and with the U.S. Securities and
Exchange Commission on EDGAR at www.sec.gov. Although the
forward-looking statements contained in this news release are based
upon what management of the Company believes, or believed at the
time, to be reasonable assumptions, the Company cannot assure
shareholders that actual results will be consistent with such
forward-looking statements, as there may be other factors that
cause results not to be as anticipated, estimated or intended.
Readers should not place undue reliance on the forward-looking
statements and information contained in this news release. The
Company assumes no obligation to update the forward-looking
statements of beliefs, opinions, projections, or other factors,
should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about
Cybin's proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds or
nutraceutical products. The efficacy of such products has not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat,
cure or prevent any disease or condition. Vigorous scientific
research and clinical trials are needed. Cybin has not conducted
clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin's
performance and operations.
Neither the Neo Exchange Inc. nor the NYSE American LLC
stock exchange have approved or disapproved the contents of this
news release and are not responsible for the adequacy and accuracy
of the contents herein.
Contacts
Investor Contacts:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media Contact:
John Kanakis
Cybin Inc.
John@cybin.com
Cybin (NEO:CYBN)
Historical Stock Chart
From May 2024 to Jun 2024
Cybin (NEO:CYBN)
Historical Stock Chart
From Jun 2023 to Jun 2024